16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association of Atopic Dermatitis With Sleep Quality in Children

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          Do children with atopic dermatitis experience impaired sleep duration and sleep quality throughout childhood, and do disease severity and activity affect their sleep?

          Findings

          In this longitudinal cohort study of 13 988 children, atopic dermatitis was statistically significantly associated with impaired sleep quality but not sleep duration throughout childhood. Sleep impairment was more common among children with more severe disease and with comorbid asthma or allergic rhinitis, and the risk remained elevated even among children with mild and inactive atopic dermatitis.

          Meaning

          These findings suggest that clinicians should consider sleep quality among all children with atopic dermatitis, especially those with comorbid asthma or allergic rhinitis and severe disease; it appears interventions to improve sleep quality are needed for this population.

          Abstract

          Importance

          Pruritus, a hallmark of atopic dermatitis (AD), is thought to disrupt sleep, yet little is known about how variations in disease activity and severity of this common childhood condition may be associated with sleep patterns over time.

          Objective

          To determine whether children with active AD have impaired sleep duration and quality at multiple time points throughout childhood and whether disease severity affects sleep outcomes.

          Design, Setting, and Participants

          This longitudinal cohort study used data of children enrolled in the Avon Longitudinal Study of Parents and Children, a population-based birth cohort in Avon, United Kingdom. Participants were children (N = 13 988) alive at 1 year and followed up with repeated measures of self-reported AD and sleep through 16 years of age. This study was based on data collected from 1990 to 2008. Data analysis was performed from September 2017 to September 2018.

          Main Outcomes and Measures

          Standardized measure of sleep duration and composite measure of sleep quality, including nighttime awakenings, early morning awakenings, difficulty falling asleep, and nightmares, were repeated at multiple time points between 2 and 16 years of age.

          Results

          The study sample comprised 13 988 children (7220 male [51.6%]) followed up for a median (interquartile range [IQR]) duration of 11 (5-14) years. Of this total, 4938 children (35.3%) met the definition of having atopic dermatitis between 2 and 16 years of age. Total sleep duration was similar between children with active AD and without AD at all ages, and the average estimated difference across childhood was a clinically negligible difference of 2 minutes less per day for children with AD (95% CI, −4 to 0 minutes). In contrast, children with active AD were more likely to report worse sleep quality at all time points, with a nearly 50% higher odds of experiencing more sleep-quality disturbances (adjusted odds ratio [aOR], 1.48; 95% CI, 1.33 to 1.66). Children with more severe active disease (quite bad or very bad AD: aOR, 1.68; 95% CI, 1.42 to 1.98) and with comorbid asthma or allergic rhinitis (aOR, 1.79; 95% CI, 1.54 to 2.09) had worse sleep quality. However, even children with mild AD (OR, 1.40; 95% CI, 1.27 to 1.54) or inactive AD (OR, 1.41; 95% CI, 1.28 to 1.55) had statistically significantly increased odds of impaired sleep quality.

          Conclusions and Relevance

          Atopic dermatitis appeared to be associated with impaired sleep quality throughout childhood; thus, it is suggested that clinicians should consider sleep quality among all children with AD, especially those with comorbid asthma or allergic rhinitis and severe disease, and that interventions to improve sleep quality are needed.

          Abstract

          This cohort study examines the prevalence and severity of atopic dermatitis as well as sleep duration and quality at multiple periods among young children enrolled in the Avon Longitudinal Study of Parents and Children in the United Kingdom.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology

          Asthma, hay fever (or allergic rhinitis) and eczema (or atopic dermatitis) often coexist in the same individuals1, partly because of a shared genetic origin2–4. To identify shared risk variants, we performed a genome-wide association study (GWAS, n=360,838) of a broad allergic disease phenotype that considers the presence of any one of these three diseases. We identified 136 independent risk variants (P<3x10-8), including 73 not previously reported, which implicate 132 nearby genes in allergic disease pathophysiology. Disease-specific effects were detected for only six variants, confirming that most represent shared risk factors. Tissue-specific heritability and biological process enrichment analyses suggest that shared risk variants influence lymphocyte-mediated immunity. Six target genes provide an opportunity for drug repositioning, while for 36 genes CpG methylation was found to influence transcription independently of genetic effects. Asthma, hay fever and eczema partly coexist because they share many genetic risk variants that dysregulate the expression of immune-related genes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema.

            The misery of living with atopic eczema (syn. dermatitis, AD) cannot be overstated for it may have a profoundly negative effect on the health-related quality of life (HRQoL) of children and their family unit in many cases. As it is one of the commonest chronic relapsing childhood dermatosis (UK lifetime prevalence 16-20% by 20 years), with increasing worldwide prevalence, this has major social and financial implications for individuals, healthcare providers and society as a whole. This review explores the impact of AD on the lives of children and their family units and the use of some of the recently developed HRQoL measures, which have enabled investigation and categorisation of the physical, psychological and psycho-social effects of childhood eczema across all aspects of life. These effects include symptoms of itching and soreness, which cause sleeplessness in over 60%. Sleep deprivation leads to tiredness, mood changes and impaired psychosocial functioning of the child and family, particularly at school and work. Embarrassment, comments, teasing and bullying frequently cause social isolation and may lead to depression or school avoidance. The child's lifestyle is often limited, particularly in respect to clothing, holidays, staying with friends, owning pets, swimming or the ability to play or do sports. Restriction of normal family life, difficulties with complicated treatment regimes and increased work in caring for a child with eczema lead to parental exhaustion and feelings of hopelessness, guilt, anger and depression. The hidden costs involved in eczema management can be significant and have particular impact on lower income families. The impairment of quality of life caused by childhood eczema has been shown to be greater than or equal to other common childhood diseases such as asthma and diabetes, emphasising the importance of eczema as a major chronic childhood disease. HRQoL measures are proving to be valuable tools for use in the clinical setting, as outcome measures for pharmaceutical studies, for health economics and audit purposes. It is therefore recommended that in future, they should be used in conjunction with objective measures of severity, as part of the assessment process of a child with atopic eczema. Lack of information on eczema and treatments heightens parental anxiety. Education of all individuals involved in the care of children with eczema is fundamental in the management of AD and it is essential to provide simple clear, unambiguous information on treatment and disease management in order to reduce the negative impact on HRQoL.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases.

              Chronic disease can have physical and psychological effects which affect social functioning. These effects can be better understood from the perspective of parent and child by the use of health-related quality of life (HRQL) measures. Various HRQL measures are now available, of which generic health measures have been the most widely used. These permit comparison between different diseases and also the normal population. To cross-validate a new generic HRQL proxy measure for children, the Children's Life Quality Index (CLQI), with an established speciality-specific dermatological questionnaire, the Children's Dermatology Life Quality Index (CDLQI), in a group of children with chronic skin diseases. The impairment of HRQL in the same group of children with skin disease was then compared with that associated with other common chronic childhood diseases using the CLQI. The CDLQI was completed by 379 children aged 5-16 years with skin disease of more than 6 months' duration. Their parents (n=379) and parents of 161 children aged 5-16 years with other chronic diseases were also asked to complete a proxy measure, the CLQI. Using linear regression analysis, the CLQI and the CDLQI scores showed a strong linear association (rs=0.72, P<0.001) and on a Bland-Altman plot, reasonably good agreement (expressing scores out of 100, the 95% limits of agreement were from -25.5/100 to 26.7/100). In the child's opinion psoriasis and atopic dermatitis (AD) caused the greatest impairment (CDLQI scores of 30.6% and 30.5%), followed by urticaria (20%) and acne (18%). Using the generic CLQI (scored 0-36), from the parental perspective the highest score was for AD (33%), followed by urticaria (28%), psoriasis (27%) and alopecia (19%). Comparing this with children with other chronic diseases, those with cerebral palsy had the highest score (38%), followed in descending order by those with generalized AD (33%), renal disease (33%), cystic fibrosis (32%), urticaria (28%), asthma (28%) and psoriasis (27%). Diseases such as epilepsy (24%) and enuresis (24%) scored higher than diabetes (19%), localized eczema (19%), alopecia (19%) and acne (16%). Using the CLQI we have shown that HRQL impairment in children with chronic skin disease is at least equal to that experienced by children with many other chronic diseases of childhood, with AD and psoriasis having the greatest impact on HRQL among chronic skin disorders and only cerebral palsy scoring higher than AD. Cross-validation of the CLQI with the CDLQI in the group of children with skin disease demonstrates a strong linear association and good agreement between the two.
                Bookmark

                Author and article information

                Journal
                JAMA Pediatr
                JAMA Pediatr
                JAMA Pediatr
                JAMA Pediatrics
                American Medical Association
                2168-6203
                2168-6211
                4 March 2019
                May 2019
                4 March 2019
                : 173
                : 5
                : e190025
                Affiliations
                [1 ]Department of Dermatology Program for Clinical Research, University of California, San Francisco, San Francisco
                [2 ]Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
                [3 ]Department of Psychiatry, University of California, San Francisco, San Francisco
                [4 ]Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco
                [5 ]Department of Pediatrics, University of California, San Francisco, San Francisco
                [6 ]Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco
                [7 ]Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee
                Author notes
                Article Information
                Accepted for Publication: January 6, 2019.
                Published Online: March 4, 2019. doi:10.1001/jamapediatrics.2019.0025
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Ramirez FD et al. JAMA Pediatrics.
                Corresponding Author: Katrina Abuabara, MD, MA, MSCE, Department of Dermatology Program for Clinical Research, University of California, San Francisco, 2341 Sutter St, Ste N421, San Francisco, CA 94115 ( katrina.abuabara@ 123456ucsf.edu ).
                Author Contributions: Dr Abuabara and Ms Ramirez had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Ramirez, Abuabara.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Ramirez, Chen, Prather, Cabana, Abuabara.
                Critical revision of the manuscript for important intellectual content: Chen, Langan, Prather, McCulloch, Kidd, Cabana, Chren, Abuabara.
                Statistical analysis: Ramirez, Chen, McCulloch, Kidd, Abuabara.
                Obtained funding: Abuabara.
                Administrative, technical, or material support: Cabana.
                Supervision: Langan, Prather, Abuabara.
                Conflict of Interest Disclosures: Ms Ramirez reported receiving grants from the National Institutes of Health (NIH) during her work on this study. Dr Langan reported receiving grants from Wellcome Senior Clinical Fellowship in Science during his work on the study. Dr McCulloch reported receiving grants from the NIH during his work on the study. Dr Abuabara reported receiving grants for atopic dermatitis from the National Eczema Association, Dermatology Foundation, Robert Wood Johnson Foundation, and National Institute of Arthritis and Musculoskeletal and Skin Diseases, as well as paid consulting for TARGETPharma, a company developing a prospective atopic dermatitis registry. No other disclosures were reported.
                Funding/Support: This study was primarily funded by a competitive research grant from the National Eczema Association. Additional personnel costs were funded by UCSF-CTSI grant number TL1TR001871 from the NIH Center for Advancing Translational Sciences (FR), the Dermatology Foundation, and the Robert Wood Johnson Foundation (Dr Abuabara); grant number KL2TR001870 from the NIH (Drs Abuabara and McCulloch); and a Wellcome Senior Clinical Fellowship in Science 17 (205039/Z/16/Z; Dr Langan). The UK Medical Research Council and Wellcome (grant 102215/2/13/2) and the University of Bristol provide core support for the Avon Longitudinal Study of Parents and Children (ALSPAC). This study was the work of the authors who serve as guarantors for the contents of this article.
                Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Disclaimer: The contents are solely the responsibility of the authors and do not necessarily represent the official views of the funders.
                Additional Contributions: The authors are grateful to Torsten Neilands, PhD, University of California, San Francisco, for guidance on the imputation process. Dr Neilands received compensation for his contribution. We are also grateful to all the families who participated in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses.
                Article
                poi190001
                10.1001/jamapediatrics.2019.0025
                6503516
                30830151
                dc1761b6-ed8e-43ec-af82-4dcb196f31cf
                Copyright 2019 Ramirez FD et al. JAMA Pediatrics.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 13 September 2018
                : 21 December 2018
                : 6 January 2019
                Categories
                Research
                Research
                Original Investigation
                Featured
                Online First
                Online Only

                Comments

                Comment on this article